SPIA
MLTX icon

Steward Partners Investment Advisory’s MoonLake Immunotherapeutics MLTX Stock Holding History

Steward Partners Investment Advisory’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.55K Buy
244
+149
+157% +$2.47K ﹤0.01% 3828
2025
Q4 		$1.25K Hold
95
– – ﹤0.01% 4052
2025
Q3 		$681 Buy
+95
New +$4.95K ﹤0.01% 4089
2023
Q4 		– Sell
-200
Closed -$11.4K – 3534
2023
Q3 		$11.4K Buy
+200
New +$11K ﹤0.01% 2546

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Steward Partners Investment Advisory's MLTX Position: Q1 2026 in Review

Steward Partners Investment Advisory increased its MoonLake Immunotherapeutics (MLTX) stake by 157% in Q1 2026, buying an estimated $2.47K and bringing the position to 244 shares worth $4.55K. The position accounts for ﹤0.01% of the portfolio, ranked #3828.

Steward Partners Investment Advisory first reported a position in MLTX in Q3 2023 and has held it in 4 quarters since. The position peaked at $11.4K in Q3 2023. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Steward Partners Investment Advisory held 244 shares of MoonLake Immunotherapeutics worth $4.55K as of Q1 2026.
  • Steward Partners Investment Advisory bought 149 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $2.47K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q1 2026, its #3828 holding.
  • Steward Partners Investment Advisory first reported a position in MoonLake Immunotherapeutics in Q3 2023 and has held it in 4 quarters since.
  • Steward Partners Investment Advisory's MoonLake Immunotherapeutics position peaked at $11.4K in Q3 2023.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q1 2026, filed 8 May 2026.